Clinical and economic effects of suboptimally controlled asthma

Managed Care Interface

Volumn 17, Issue 1, 2004, Pages 31-36

  Bootman, J Lyle ^a   Crown, William H ^b   Luskin, Allan T ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Outcomes Research and Econometrics   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; OMALIZUMAB; PLACEBO; THEOPHYLLINE;

ADOLESCENT; ADULT; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; COST OF ILLNESS; FEMALE; HEALTH SERVICES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MALE; PREVALENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 0347133325     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. National Center for Health Statistics: Asthma prevalence, health care use and mortality, 2000-2001. Centers for Disease Control, March 19, 2003 (www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm).
2. Trends in Asthma Morbidity and Mortality. American Lung Association, March 2003 (www.lungusa.org/data/asthma/asthma1.pdf).
3. Smith DH, Malone DC, Lawson KA, et al: A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:787-793.
4. Beasley R: The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109(suppl):482-489.
5. National Asthma Education and Prevention Program: Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD, National Institutes of Health publication No. 97-4051, April 1997.
6. Colice GL, Vanden Burgt J, Song J, et al: Categorizing asthma severity. Am J Respir Crit Care Med 1999;160:1962-1967.
7. Osborne ML, Vollmer WM, Pedula KL, et al: Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest 1999;115:85-91.
8. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al: The burden of asthma in the United States. Am J Respir Crit Care Med 2002;166:1044-1049.
9. Wenzel S: Physician-based assessment of asthma severity may exceed that estimated from guideline parameters (abstract). Am J Respir Crit Care Med 2002;165:A119.
10. Auerbach I, Springer C, Godfrey S: Total population survey of the frequency and severity of asthma in 17 year old boys in an urban area of Israel. Thorax 1993;48:139-141.
11. Crystal-Peters J, Neslusan C, Crown WH, et al: Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57-62.
12. Weiss KB, Sullivan SD: The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8.
13. Asthma in America Survey, Executive Summary. Asthma in America, September 4, 2003 (www.asthmainamerica.com/execsum_over.htm).
14. American Thoracic Society: Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-2351.
15. Woolcock AJ: Worldwide differences in asthma prevalence and mortality. Chest 1986;90(suppl):40-45.
16. Serra-Batlles J, Plaza V, Morejon E, et al: Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-1326.
17. Godard P, Chanez P, Siraudin L, et al: Costs of asthma are correlated with severity: A 1-yr prospective study. Eur Respir J 2002;19:61-67.
18. Global Initiative for Asthma: Pocket Guide for Asthma Management and Prevention. U.S. Dept. of Health and Human Services publication No. (NIH) 96-3659B, November 1998.
19. Rea HH, Scragg R, Jackson R, et al: A case control study of deaths from asthma. Thorax 1986;41:833-839.
20. Crane J, Pearce N, Burgess C, et al: Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737-744.
21. Tough SC, Hessel PA, Ruff M, et al: Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-665.
22. Barnes PJ, Johsson B, Klim JB: The costs of asthma. Eur Respir J 1996;9:636-642.
23. Hoskins G, McCowan C, Neville RG, et al: Risk factors and costs associated with an asthma attack. Thorax 2000;55:19-24.
24. Hayden M: High level health care utilization in severe and difficult-to-treat asthma (abstract). J Allergy Clin Immunol 2002;109(suppl):293.
25. Holgate S, Bousquet J, Wenzel S, et al: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233-240.
26. Szefler SJ, Martin RJ, King TS, et al: Asthma Clinical Research Network of the National Heart Lung, and Blood Institute: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-418.
27. Bender B, Milgrom H, Rand C: Nonadherence in asthmatic patients: Is there a solution to the problem? Ann Allergy Asthma Immunol 1997;79:177-185.
28. Bender B, Wamboldt FS, O'Connor SL, et al: Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT. Ann Allergy Asthma Immunol 2000;85:416-421.
29. Rand CS, Wise RA, Nides M, et al: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992;146:1559-1564.
30. Apter AJ, Reisine ST, Affleck G, et al: Adherence with twice-daily dosing of inhaled steroids: Socioeconomic and health-belief differences. Am J Respir Crit Care Med 1998;157:1810-1817.
31. Drazen JM, Boccuzzi SJ, Wogen J, et al: Adherence to prescribed treatment for asthma (abstract). Am J Respir Crit Care Med 2000;161:A402.
32. Cramer JA, Mattson RH, Prevey ML, et al: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277.
33. Milgrom H, Bender B, Ackerson L, et al: Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 suppl 1):1051-1057.
34. Suissa S, Ernst P, Benayoun S, et al: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-336.
35. Suissa S, Ernst P, Kezouh A: Regular use of inhaled corticosteroids and the long term prevention of hospitalization for asthma. Thorax 2002;57:880-884.
36. Beeh KM, Ksoll M, Buhl R: Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J 2000;16:609-614.
37. Busse WW, Lemanske RF: Asthma. N Engl J Med 2001;344:350-362.
38. Burrows B, Martinez FD, Halonen M, et al: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
39. Sears MR, Burrows B, Flannery EM, et al: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:1067-1071.
40. Sunyer J, Munoz A: Concentrations of methacholine for bronchial responsiveness according to symptoms, smoking and immunoglobulin E in a population-based study in Spain. Spanish Group of the European Asthma Study. Am J Respir Crit Care Med 1996;153:1273-1279.
41. Soler M, Matz J, Townley R, et al: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261.
42. Busse W, Corren J, Lanier BQ, et al: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
43. Corren J, Casale T, Deniz Y, et al: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.
44. Shrewsbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-1373.
45. Blais L, Ernst P, Boivin JF, et al: Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998;158:126-132.
46. Rosenwasser LJ, Nash DB: Incorporating omalizumab into asthma treatment guidelines: Consensus panel recommendations. P&T 2003;28:400-414.